Logo

St. Gallen

'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
Premium

Originally published Aug. 16. By Turna Ray

St. Gallen's Recommendations May Impact Adoption of Leading Breast Cancer Genetic Tests
Premium

The recommendations by the expert group, which met in Switzerland in March and involves healthcare leaders from around the world, could impact the reimbursement and adoption of breast cancer genetic tests, such as Agendia's MammaPrint and Genomic Health's Oncotype DX.